Newswise — Feb. 10, 2017─In the largest epidemiological study conducted in the developing world, researchers found that as exposures to fine particulate air pollution in 272 Chinese cities increase, so do deaths from cardiovascular and respiratory diseases. The researchers reported their results in “Fine Particulate Air Pollution and Daily Mortality: A Nationwide Analysis in 272 Chinese Cities,” published online ahead of print in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.
“Fine particulate [PM2.5] air pollution is one of the key public health concerns in developing countries including China, but the epidemiological evidence about its health effects is scarce,” said senior study author Maigeng Zhou, PhD, deputy director of the National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention. “A new monitoring network allowed us to conduct a nationwide study to evaluate short-term associations between PM2.5 and daily cause-specific mortality in China.”
The researchers found: • The average annual exposure to PM2.5 in the Chinese cities was 56 micrograms per cubic meter (µg/m3)—well above the World Health Organization air quality guidelines of 10 µg/m3.• Each 10 µg/m3 increase in air pollution was associated with a 0.22 percent increase in mortality from all non-accident related causes. • Each 10 µg/m3 increase in air pollution was associated with a 0.29 percent increase in all respiratory mortality and a 0.38 percent increase in chronic obstructive pulmonary disease (COPD) mortality. • Mortality was significantly higher among people age 75 and older and among people with lower levels of education.• The association between PM2.5 levels and mortality was stronger in cities with higher average annual temperatures.
The researchers speculate that differences in educational attainment may result in environmental health inequalities and access to health care that affect mortality. In warmer cities, the authors hypothesize residents may spend more time outdoors and open windows, increasing their exposure to PM2.5.
The researchers said their study suggests a weaker association between increases in PM2.5 and mortality than studies conducted in Europe and North America. They suggest a number of possible explanations for this difference, including that in most Chinese cities there was a plateauing of mortality at the highest levels of pollution and the components of PM2.5 pollution in China may be less toxic than the components in Europe and North America. Crustal dust from arid lands and construction make up more PM2.5 pollution in China than it does in Europe and North America.
In 2013 China began introducing PM2.5 monitoring in urban areas. The current study analyzed available data between 2013-15. For nearly half the cities in the study, there was only one year of PM2.5 data available, and the authors note that a limitation of their study is that it does not look at the cumulative effect of PM2.5 over many years.
“Our findings may be helpful to formulate public health policies and ambient air quality standards in developing countries to reduce the disease burden associated with PM2.5 air pollution,” said study co-author Haidong Kan, MD, professor of public health at Fudan University in China. “Further massive investigations, especially looking at the long-term effect studies, are needed to confirm our results and to identify the most toxic components of PM2.5 in China.”
The study was funded mainly by the Public Welfare Research Program of National Health and Family Planning Commission of China, the National Science Foundation of China and the China Medical Board Collaborating Program.
Contacts for article: Maigeng Zhou, PhD Phone: +86 (10) 6304-2350Email: [email protected]
Haidong Kan, MDPhone: +86 (21) 5423 7908 Email: [email protected]
Share via Twitter“Study of #airpollution in #China finds increased respiratory and CVD deaths.”
Follow UsATS - @atscommunityAJRCCM - @ATSBlueEditor
About the American Journal of Respiratory and Critical Care Medicine (AJRCCM):The AJRCCM is a peer-reviewed journal published by the American Thoracic Society. The Journal takes pride in publishing the most innovative science and the highest quality reviews, practice guidelines and statements in pulmonary, critical care and sleep medicine. With an impact factor of 12.996, it is the highest ranked journal in pulmonology. Editor: Jadwiga Wedzicha, MD, professor of respiratory medicine at the National Heart and Lung Institute (Royal Brompton Campus), Imperial College London, UK.About the American Thoracic Society:Founded in 1905, the American Thoracic Society is the world's leading medical association dedicated to advancing pulmonary, critical care and sleep medicine. The Society’s 15,000 members prevent and fight respiratory disease around the globe through research, education, patient care and advocacy. The ATS publishes three journals, the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and the Annals of the American Thoracic Society.The ATS will hold its 2017 International Conference, May 19-24, in Washington, DC, where world-renowned experts will share the latest scientific research and clinical advances in pulmonary, critical care and sleep medicine.
MEDIA CONTACTRegister for reporter access to contact details
American Journal of Respiratory and Critical Care Medicine